57 related articles for article (PubMed ID: 19665247)
21. Retreatment with interferon-alpha at dosages or period increased by 1.3 times is effective for treatment for transient responders and non-responders in chronic hepatitis C patients.
Okanoue T; Daimon Y; Kirishima T; Ohnishi N; Nakamura H; Nagao Y; Minami M; Itoh Y
Hepatol Res; 2001 Jul; 20(3):348-358. PubMed ID: 11404194
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?
Aghemo A; Colombo M
Gastroenterology; 2012 Dec; 143(6):1685-7. PubMed ID: 23073135
[No Abstract] [Full Text] [Related]
23. PEGylated interferon plus ribavirin in chronic hepatitis C.
Bacon BR
Curr Gastroenterol Rep; 2001 Feb; 3(1):11. PubMed ID: 11177688
[No Abstract] [Full Text] [Related]
24. Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort.
Licata A; Minissale MG; Giannitrapani L; Montalto FA; Lombardo C; Mirarchi L; Amodeo S; Soresi M; Montalto G
Intern Emerg Med; 2022 Jan; 17(1):43-51. PubMed ID: 33909256
[TBL] [Abstract][Full Text] [Related]
25. APASL consensus statements and management algorithms for hepatitis C virus infection.
Omata M; Kanda T; Yu ML; Yokosuka O; Lim SG; Jafri W; Tateishi R; Hamid SS; Chuang WL; Chutaputti A; Wei L; Sollano J; Sarin SK; Kao JH; McCaughan GW
Hepatol Int; 2012 Apr; 6(2):409-35. PubMed ID: 26201405
[TBL] [Abstract][Full Text] [Related]
26. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.
Bonnet D; Guivarch M; Bérard E; Combis JM; Remy AJ; Glibert A; Payen JL; Metivier S; Barange K; Desmorat H; Palacin A; Nicot F; Abravanel F; Alric L
World J Hepatol; 2014 Sep; 6(9):660-9. PubMed ID: 25276282
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C.
Brogan AJ; Talbird SE; Thompson JR; Miller JD; Rubin J; Deniz B
PLoS One; 2014; 9(3):e90295. PubMed ID: 24603445
[TBL] [Abstract][Full Text] [Related]
28. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin.
Abbas Z; Tayyab GN; Qureshi M; Memon MS; Subhan A; Shakir T; Jafri W; Hamid S
Hepat Mon; 2013; 13(12):e14146. PubMed ID: 24358041
[TBL] [Abstract][Full Text] [Related]
29. Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea.
Cho HC; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
Gut Liver; 2013 Sep; 7(5):585-93. PubMed ID: 24073317
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
Chhatwal J; Ferrante SA; Brass C; El Khoury AC; Burroughs M; Bacon B; Esteban-Mur R; Elbasha EH
Value Health; 2013; 16(6):973-86. PubMed ID: 24041347
[TBL] [Abstract][Full Text] [Related]
31. Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS; Aspinall E; Liew D; Thompson AJ; Hellard ME
Br J Clin Pharmacol; 2013 Apr; 75(4):931-43. PubMed ID: 22882367
[TBL] [Abstract][Full Text] [Related]
32. Peginterferon and ribavirin treatment for hepatitis C virus infection.
Tsubota A; Fujise K; Namiki Y; Tada N
World J Gastroenterol; 2011 Jan; 17(4):419-32. PubMed ID: 21274371
[TBL] [Abstract][Full Text] [Related]
33. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.
Feld JJ; Modi AA; El-Diwany R; Rotman Y; Thomas E; Ahlenstiel G; Titerence R; Koh C; Cherepanov V; Heller T; Ghany MG; Park Y; Hoofnagle JH; Liang TJ
Gastroenterology; 2011 Mar; 140(3):830-9. PubMed ID: 20854821
[TBL] [Abstract][Full Text] [Related]
34. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Di Martino V; Richou C; Cervoni JP; Sanchez-Tapias JM; Jensen DM; Mangia A; Buti M; Sheppard F; Ferenci P; Thévenot T
Hepatology; 2011 Sep; 54(3):789-800. PubMed ID: 21674553
[TBL] [Abstract][Full Text] [Related]
35. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
Deltenre P; Louvet A; Lemoine M; Mourad A; Fartoux L; Moreno C; Henrion J; Mathurin P; Serfaty L
J Hepatol; 2011 Dec; 55(6):1187-94. PubMed ID: 21703195
[TBL] [Abstract][Full Text] [Related]
36. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
[TBL] [Abstract][Full Text] [Related]
37. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Mangia A; Mottola L; Piazzolla V
Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
[TBL] [Abstract][Full Text] [Related]
38. [Retreatment strategies for the patients with HCV infection].
Pawłowska M
Przegl Epidemiol; 2005; 59(2):591-4. PubMed ID: 16190570
[TBL] [Abstract][Full Text] [Related]
39. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Cammà C; Cabibbo G; Bronte F; Enea M; Licata A; Attanasio M; Andriulli A; Craxì A
J Hepatol; 2009 Oct; 51(4):675-81. PubMed ID: 19665247
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
